It is very uncertain whether late (seven days or more following birth) higher changes mortality (latest time reported up to hospital discharge) compared with lower sodium intake (very low certainty).
Early (less than seven days following birth) higher showed no clear difference in mortality (latest time reported up to hospital discharge) compared with lower sodium intake (low certainty).
Higher showed no clear difference in mortality to hospital discharge compared with lower amino acid intake (low certainty).
It is very uncertain whether higher changes all‐cause mortality: range 1 mo to 1 y compared with lower FiO2 or targets of arterial oxygenation (very low certainty).
Higher showed no clear difference in all‐cause mortality Study duration range 12‐96 months Omega‐6 dose… compared with lower omega‐6: primary outcomes (low certainty).
It is very uncertain whether higher changes cardiovascular mortality Study duration range 24‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (very low certainty).
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for all-cause mortality (11 studies, I2=89%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for ACVD-related events (13 studies, I2=75%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
Higher‐dose anticoagulants showed no clear difference in all‐cause mortality compared with lower‐dose anticoagulants (high certainty).
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in all‐cause mortality compared with lower PUFA (moderate certainty).
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
Meta-analysis of observational studies (higher vs lower 25(OH)D) for All cause mortality, Patients with chronic kidney disease: RR 0.86 (95% CI 0.81 to 0.92), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for All cause mortality: HR 0.72 (95% CI 0.66 to 0.78), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
The review found no eligible studies for this question.
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in cardiovascular mortality compared with lower PUFA (low certainty).
It is very uncertain whether higher threshold (500 mL per six hours or greater) changes mortality (at the end of compared with lower threshold (less than 500 mL per six hours) at time of aspiration (very low certainty).
Higher dose vitamin K showed no clear difference in mortality (all infants): 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease mortality compared with lower PUFA (low certainty).
The meta-analysis of observational studies reported a RR of 0.88 (95% CI 0.81 to 0.93) for higher versus lower circulating vitamin D concentration.